

CAB39 Polyclonal Antibody

catalog number: E-AB-13421

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Reactivity	Human;Mouse
Immunogen	Synthetic peptide of human CAB39
Host	Rabbit
Isotype	IgG
Purification	Affinity purification
Buffer	Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol.

Applications


Applications	Recommended Dilution
WB	1:500-1:2000
IHC	1:50-1:200

Data




Western Blot analysis of 293T and LoVo cell, Human brain malignant glioma tissue using CAB39 Polyclonal Antibody at dilution of 1:450

Calculated-MW:40 kDa



Immunohistochemistry of paraffin-embedded Human gastric cancer using CAB39 Polyclonal Antibody at dilution of 1:50



Immunohistochemistry of paraffin-embedded Human malignant glioma tissue using CAB39 Polyclonal Antibody at dilution of 1:50

Preparation & Storage

Storage	Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
Shipping	The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

Background

For Research Use Only

Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).

For Research Use Only

Toll-free: 1-888-852-8623
Web: www.elabscience.com

Tel: 1-832-243-6086
Email: techsupport@elabscience.com

Fax: 1-832-243-6017

Rev. V1.7